Education
About Us
Working with TipRanks
Follow Us
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
GLMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $5.20
Previous CloseN/A
Volume19.24K
Average Volume (3M)161.49K
Market Cap
$8.49M
Enterprise Value-$13.39M
Total Cash (Recent Filing)$15.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding5,479,231
10 Day Avg. Volume55,551
30 Day Avg. Volume161,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit161.28
Enterprise Value/Ebitda2.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Partnerships And CollaborationsGalmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.
Product DevelopmentGalmed signed a term sheet with Entomus to develop a sublingual GLP-1 compound, potentially treating obesity, which led to a significant increase in shares.
Bears Say
Clinical TrialsThe company halted the Phase 3 trial for Aramchol meglumine due to financial and enrollment issues.
Strategic UncertaintyGalmed's strategic positioning and path forward remains unclear.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $1.15 and its highest was $5.20 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $8.49M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 20, 2026 which is in 229 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.83 by $0.2.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 5,479,231 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.83. Following the earnings report the stock price went down -3.55%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Technical Analysis
Matinas BioPharma
―
Hepion Pharmaceuticals
―
Quoin Pharmaceuticals
―
InMed Pharmaceuticals
―
Galecto
―
Ownership Overview
6.20%
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---